[1]Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[2]Poon RT, Fan S T. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome[J]. Liver Transpl, 2004, 10 (2 Suppl 1): S39-45.
[3]Sun S, Xu MZ, Poon RT, et al. Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients[J]. J Proteome Res, 2010, 9(1): 70-78.
[4]Zinkin NT, Grall F, Bhaskar K, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease[J]. Clin Cancer Res, 2008, 14(2): 470-477.
[5]Bruix J, Sherman M. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53(3): 1020-1022.
[6]Kornfeld R, Kornfeld S. Assembly of asparagine-linked oligosaccharides[J]. Annu Rev Biochem, 1985, 54(6): 631-641.
[7]Wong CH. Protein glycosylation: new challenges and opportunities[J]. J Org Chem, 2005, 70(11): 4219-4225.
[8]Wang M, Huang ZhH, Lei P, et al. Proteomic profiling of N-linked glycoproteins involved in hepatocellular carcinoma by two-dimensional electrophoresis and mass spectrometry[J]. Chinese Journal of Biochemistry and Molecular Biology, 2013, 29(5): 482-489.(in Chinese)
王明,黄志红,雷鹏,等. 二维电流和质谱技术鉴定肝癌血清差异表达的N-连接糖蛋白[J]. 中国生物化学与分子生物学报,2013,29(5):482-489.
[9]Lee NP, Chen L, Lin MC, et al. Proteomic expression signature distinguishes cancerous and nonmalignant tissues in hepatocellular carcinoma[J]. J Proteome Res, 2009, 8(3): 1293-1303.
[10]Wright LM, Kreikemeier JT, Fimmel CJ. A concise review of serum markers for hepatocellular cancer[J]. Cancer Detect Prev, 2007, 31(1): 35-44.
[11]Yang Z, Hancock WS, Chew TR, et al. A study of glycoproteins in human serum and plasma reference standards (HUPO) using multilectin affinity chromatography coupled with RPLC-MS/MS[J]. Proteomics, 2005, 5(13): 3353-3366.
[12]Anderson N, Pollacchi A, Hayes P, et al. A preliminary evaluation of the differences in the glycosylation of alpha-1-acid glycoprotein between individual liver diseases[J]. Biomed Chromatogr, 2002, 16(6): 365-372.
[13]Ihara S, Miyoshi E, Ko JH, et al. Prometastatic Effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding β1-6 GlcNAc branching[J]. J Biol Chem, 2002, 277(19): 16960-16967.
[14]Zhang S, Shu H, Luo K, et al. N-linked glycan changes of serum haptoglobin beta chain in liver disease patients[J]. Mol Biosyst, 2011, 7(5): 1621-1628.
[15]Yoon SK. Recent advances in tumor markers of human hepatocellular carcinoma[J]. Intervirology, 2008, 51( Suppl 1): 34-41.
[16]Capony F, Rougeot C, Montcourrier P, et al. Increased secretion, altered processing, and glycosylation of pro-cathepsin D in human mammary cancer cells[J]. Cancer Res, 1989, 49(14): 3904-3909.
[17]Brouillet JP, Spyratos F, Hacene K, et al. Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: relative prognostic value versus total cathepsin D[J]. Eur J Cancer, 1993, 29A(9): 1248-1251.
[18]Ohri SS, Vashishta A, Vetvickova J, et al. Procathepsin D expression correlates with invasive and metastatic phenotype of MDA-MB-231 derived cell lines[J]. Int J Biol Macromol, 2007, 41(2): 204-209.
[19]Liaudet-Coopman E, Beaujouin M, Derocq D, et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis[J]. Cancer Lett, 2006, 237(2): 167-179.
[20]Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells[J]. J Med Invest, 2005, 52(1-2): 1-9.
[21]Qin X, Gao B. The complement system in liver diseases[J]. Cell Mol Immunol, 2006, 3(5): 333-340.
[22]Abbott KL, Aoki K, Lim JM, et al. Targeted glycoproteomic identification of biomarkers for human breast carcinoma[J]. J Proteome Res, 2008, 7(4): 1470-1480.
[23]Na K, Lee EY, Lee HJ, et al. Human plasma carboxylesterase 1, a novel serologic biomarker candidate for hepatocellular carcinoma[J].Proteomics, 2009, 9(16): 3989-3999.
|